Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in China: a 2019-2021 cohort health survey

被引:0
作者
Shi, Dan [1 ]
Tan, Qilong [2 ,3 ]
Zhang, Yong [1 ,4 ]
Qi, Xiaoya [4 ]
Xu, Xiaoyang [4 ]
Xu, Guoqiong [4 ]
Bai, Ruixue [4 ]
Deng, Jing [4 ]
Chen, Mengxue [4 ]
Jiang, Tao [4 ]
Mei, Ying [4 ]
机构
[1] Chongqing Med Univ, Sch Publ Hlth, Chongqing 400016, Peoples R China
[2] Zhejiang Univ, Sch Publ Hlth, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China
[3] Harbin Med Univ, Sch Publ Hlth, Harbin 150081, Heilongjiang, Peoples R China
[4] Chongqing Med Univ, Hosp 2, Dept Hlth Management, Chongqing 400011, Peoples R China
关键词
MASLD; Uric acid; Trajectory; China; FATTY LIVER; HEPATIC STEATOSIS; HYPERURICEMIA; HYPERTENSION; GENERATION; STRESS;
D O I
10.1186/s12889-024-21214-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
ObjectiveTo investigate the associations between serum uric acid (UA) trajectories and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in large cohort survey 2019-2021.MethodsThis cohort health survey included 11,644 participants without MASLD before January 1, 2021. Among them, 5578 (47.90%) were men and 6066 (52.10%) were women. The group-based trajectory model method was applied to identify serum UA trajectories from January 1, 2019, to December 30, 2021. New-onset MASLD events in 2021 were treated as outcomes. A logistic regression model was used to assess associations between UA trajectories and incidence of MASLD.ResultsFour distinct serum UA trajectories among both sexes were identified: "low-stable" trajectory 1 (n = 783 men; n = 1143 women), "moderate-moderate increasing" trajectory 2 (n = 2794 men; n = 3266 women), "moderate high-moderate increasing" trajectory 3 (n = 1660 men; n = 1464 women), and "high-increasing" trajectory 4 (n = 341 men; n = 193 women). During the 3-year follow-up period, 840 (15.06%) men and 408 (6.72%) women developed MASLD, respectively. Compared with the trajectory 1 group, the trajectory 4 group had the highest risk (odds ration [OR] 2.99 [95% confidence interval {CI} 1.70, 5.24] for men; OR 2.37 [95% CI 1.04, 5.33] for women), followed by the trajectory 3 (OR 2.23 [95% CI 1.52, 3.30] for men; OR 2.37 [95% CI 1.45, 3.92] for women) and trajectory 2 (OR 1.43 [95% CI 1.07, 1.94] for men; OR 1.37 [95% CI 0.93, 2.03] for women) groups.ConclusionsHigh serum UA trajectories were independent risk factors for MASLD in both sexes, which is critical for informing prevention and treatment strategies in public health initiatives and clinical practice.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Serum uric acid and mortality in metabolic dysfunction-associated steatotic liver disease: Subgroup differences
    Chen, Wenya
    Deng, You
    Li, Mengqi
    Li, Jiashuo
    Cao, Ying
    Xie, Wen
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (12) : 2771 - 2778
  • [2] Serum uric acid as a biomarker for metabolic dysfunction-associated steatotic liver disease: insights from ultrasound elastography in a Chinese cohort
    Chang, Zhe
    Liu, Zhe
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [3] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [4] Dietary fructose: from uric acid to a metabolic switch in pediatric metabolic dysfunction-associated steatotic liver disease
    Faienza, Maria Felicia
    Cognetti, Eleonora
    Farella, Ilaria
    Antonioli, Alessandro
    Tini, Sabrina
    Antoniotti, Valentina
    Prodam, Flavia
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2024,
  • [5] Occupational stress trajectories and metabolic dysfunction-associated steatotic liver disease among female nurses: a prospective Cohort Study
    Luo, Hanxiao
    Xing, Linlin
    Fu, Tongtong
    Xiao, Shiqi
    Fan, Ling
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [6] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [7] Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Chronic Periodontitis: A Nationwide Cohort Study
    Shine, Bo-Kyung
    Son, Minkook
    Moon, Sang Yi
    Han, Seong-Ho
    NUTRIENTS, 2025, 17 (01)
  • [8] Metabolic dysfunction-associated steatotic liver disease in children
    Goyal, Nidhi P.
    Xanthakos, Stavra
    Schwimmer, Jeffrey B.
    GUT, 2025, : 669 - 677
  • [9] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [10] Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
    Ionescu, Vlad Alexandru
    Gheorghe, Gina
    Bacalbasa, Nicolae
    Diaconu, Camelia Cristina
    BIOMOLECULES, 2025, 15 (02)